Latest News for: Wamd

Edit

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals

PR Newswire 08 Sep 2022
79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively ... PULSAR (wAMD) ... wAMD is a retinal disease that may affect people as they age.
Edit

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, ...

The Associated Press 08 Sep 2022
79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively ... PULSAR (wAMD) ... In both PHOTON and PULSAR, patients with DME and wAMD were randomized into three treatment groups to receive either.
Edit

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals (Regeneron Pharmaceuticals Inc)

Public Technologies 08 Sep 2022
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals ... PULSAR (wAMD) ... In both PHOTON and PULSAR, patients with DME and wAMD were randomized into three treatment groups to receive either ... About DME and wAMD.
Edit

Replay KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 28 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62197168) .
Edit

Live KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 27 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62180751) .
Edit

Saudi Arabia.. “Tadawul” share jumps more than 10 percent on its first trading day

The Eastern Herald 08 Dec 2021
Saudi Stock Exchange run by Tadawul (File Photo) ... “Tadawul” includes four subsidiaries, namely, the Saudi Tadawul (as a stock market), a clearing center for securities company (clearing), the Securities Depository Center Company (Edaa), and the new Wamd Company, which specializes in services and technology solutions based on innovation.
Edit

The launch of the “Tadawul” company operating the Saudi Stock Exchange

The Eastern Herald 21 Nov 2021
Saudi flag ... “Tadawul” includes four subsidiaries, namely, the Saudi Tadawul (as a stock exchange), a clearing center for securities company (clearing), the Securities Depository Center Company (Edaa), and the new Wamd Company, which specializes in innovation-based technical services and solutions. Related. ... © The Eastern Herald ... ....
Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) (Shanghai Henlius Biotech Inc)

Public Technologies 20 Apr 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) INTRODUCTION ... macular degeneration (wAMD) indications.
Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA (Shanghai Henlius Biotech Inc)

Public Technologies 29 Jan 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA INTRODUCTION.
Edit

Opthea to Host Key Opinion Leader Symposium on wAMD and DME 2 pages ?Kb

Public Technologies 28 Jul 2020
The text version of this document in not available ... Disclaimer ... (noodl. 54775274) .
Edit

Opthea confirms final patient enrolment in Ph2b wAMD trial

Public Technologies 25 Nov 2018
ASX and Media Release 26 November 2018. Opthea Confirms Final Patient Enrolment in. Phase 2b Wet AMD Clinical Trial ... Today's announcement follows the randomization of an additional 15 patients who were undergoing eligibility screening when the Company recently successfully achieved its target enrolment of 351 treatment naïve patients into the study.
Edit

Opthea Phase 2b wAMD trial fully recruited ahead of schedule

Public Technologies 13 Nov 2018
ASX and Media Release 14 November 2018. Opthea Completes Patient Recruitment Ahead of Schedule in. Phase 2b Wet AMD Clinical Trial ... The randomization of 351 treatment naïve patients with wet AMD at 113 clinical sites in the United States, Europe and Israel was initiated in late December 2017 and has been completed ahead of the projected timelines ... Tel.
Edit

Opthea to Host wAMD and DME Key Opinion Leader Forum

Public Technologies 24 Sep 2018
ASX and Media Release 24 September 2018. Opthea to Host Wet AMD and Diabetic Macular Edema. Key Opinion Leader Forum in New York City ... The event will be held from 12.00PM - 2.00PM EST on Tuesday, November 6th, 2018 at the Parker New York Hotel in New York City ... Dr Rishi Singh, MD (Cleveland Clinic, Cleveland, OH) ... 10019-3318 ... About OPT-302 ... Curr Diab Rep.
Edit

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD

Pharmiweb 20 Sep 2018
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD ADVM-022 is a uni... .

Most Viewed

This undated photograph released by the Ukrainian military's Strategic Communications Directorate shows the wreckage of what Kyiv has described as an Iranian Shahed drone downed near Kupiansk, Ukraine
AP / Ukrainian military's Strategic Communications Directorate
From the railroad station in Cartagena in jugend style or Art Nouveau - Spain 2016 - trains
Creative Commons / Øyvind Holmstad
From the railroad station in Cartagena in jugend style or Art Nouveau - Spain 2016 - trains
Creative Commons / Øyvind Holmstad
President Cristina Fernandez de Kirchner at her second Inauguration day
Creative Commons / Presidency of Argentina.
×